Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ13231328-1,41
KB105710593,33
PKN151,18151,2-3,08
Msft388,26388,571,84
Nokia8,2668,2760,78
IBM217,67217,751,59
Mercedes-Benz Group AG4545,0150,52
PFE24,5824,590,16
27.07.2026 15:15:58
Indexy online
AD Index online
select
AD Index online
 

  • 23.07.2026 8:00:43
Cardinal Health (CAH.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
191,35 0,00 0,00 191 350
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 27.07.2026
Popis společnosti

Business Summary: Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
Financial Summary: BRIEF: For the nine months ended 31 March 2026, Cardinal Health, Inc revenues increased 17% to $190.58B. Net income remained flat at $1.32B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions., offset by Pharmaceutical and Speciality solution segment income decrease of 54% to $784M, Corporate segment loss increase of 61% to $479M, Other segment income decrease of 50% to $179M.



  • Poslední aktualizace: 27.07.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Supervisory BoardDieter Kempf7316.05.202216.05.2022
Chairman of the Executive Board, Chief Executive OfficerStefan Klebert6018.02.201915.11.2018
Deputy Chairman of the Supervisory Board - Employee RepresentativeRainer Groebel7230.04.202130.04.2021
Chief Financial Officer, Member of the Executive BoardAlexander Kocherscheidt5231.10.202531.10.2025
Chief Operating Officer, Member of the Executive BoardJohannes Giloth5520.01.202020.01.2020
Member of the Executive Board - Responsible for the Pure Flow Processing DivisionKai Becker4501.01.202601.01.2026
Member of the Executive Board - Responsible for the Pharma & Food Applications DivisionPeter Lauwers5601.01.202601.01.2026
Member of the Executive Board - Responsible for People & SustainabilityNadine Sterley4601.01.202601.01.2026
Member of the Executive Board - Responsible for the Nutrition Plant Engineering DivisionKlaus Stojentin5901.01.202601.01.2026